| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
DCVJ does not have a specific protein target but functions as a fluorescent molecular rotor that senses microviscosity. The compound's fluorescence quantum yield is highly dependent on the rotational freedom of its molecular rotor. In low-viscosity environments, the rotor can rotate freely, leading to non-radiative decay and low fluorescence. In high-viscosity environments, rotation is restricted, leading to increased fluorescence. This property makes DCVJ a valuable tool for studying membrane fluidity, protein aggregation, and cellular viscosity in biological systems.
|
|---|---|
| ln Vitro |
In vitro, DCVJ is used as a fluorescent probe to measure microviscosity in various biological systems. The compound's fluorescence intensity increases with increasing viscosity, allowing for quantitative measurements of viscosity in solutions, membranes, and protein aggregates. In cell-based assays, DCVJ is used to study membrane fluidity and cellular viscosity. Its fluorescence properties make it a valuable tool for studying the physical properties of biological membranes and for detecting protein aggregation.
|
| ln Vivo |
In vivo, DCVJ is used in live-cell imaging to study cellular viscosity and membrane fluidity. The compound can be loaded into cells, and fluorescence is detected using fluorescence microscopy. Its use in vivo is limited by potential toxicity and the need for appropriate delivery methods. The compound is primarily used as a research tool for studying microviscosity in biological systems.
|
| Enzyme Assay |
The in vitro viscosity measurement assay for DCVJ involves preparing solutions of varying viscosity (e.g., using glycerol-water mixtures) and measuring the fluorescence of the probe. The compound is dissolved in appropriate solvent and added to the solutions at a final concentration of 1-10 µM. Fluorescence is measured at excitation/emission wavelengths appropriate for the probe (typically ~440/500 nm). The fluorescence intensity is plotted against viscosity to generate a calibration curve. For biological samples, the probe is added to membranes, protein solutions, or cell lysates, and fluorescence is measured to estimate microviscosity. Positive controls (e.g., known viscous solutions) and negative controls (buffer only) are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, cells are loaded with DCVJ by incubating with the probe at 1-10 µM for 30-60 minutes at 37°C. After washing, cells are imaged using fluorescence microscopy, and the fluorescence intensity is measured to estimate cellular viscosity. For membrane fluidity studies, cells are treated with compounds that modulate membrane fluidity (e.g., cholesterol, fatty acids), and changes in DCVJ fluorescence are monitored. Cell viability is assessed using MTT or CellTiter-Glo assays to ensure that probe loading does not cause cytotoxicity. All experiments include appropriate controls (untreated cells, vehicle) and are performed in triplicate.
|
| Animal Protocol |
For in vivo imaging studies, DCVJ may be administered to animals via injection or topical application, and fluorescence is detected using appropriate imaging systems. However, specific in vivo protocols for DCVJ are not well-documented in publicly available sources. The compound is primarily used as a research tool for in vitro applications. All animal procedures should be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of DCVJ are not relevant, as it is a fluorescent probe rather than a therapeutic agent. The compound has a molecular weight of 264.36 and is cell-permeable. It is used in vitro and in vivo for microviscosity measurements. The compound should be stored protected from light to prevent photobleaching.
|
| Toxicity/Toxicokinetics |
The toxicology of DCVJ is primarily related to its use as a fluorescent probe. At the low concentrations used for viscosity measurements (1-10 µM), it is generally considered non-toxic to cells. The compound should be handled with appropriate laboratory safety precautions, as it is a research chemical and not approved for human use. Comprehensive toxicology studies would be required if the compound were to be used for therapeutic applications.
|
| References | |
| Additional Infomation |
See also: 9-(dicyanovinyl)julolide (note moved to).
DCVJ is a fluorescent molecular rotor that is sensitive to microviscosity. It exhibits increased fluorescence in viscous environments and is used to study membrane fluidity, protein aggregation, and cellular viscosity. The compound is not approved for human use and is intended for research purposes only. It is available as a high-purity research reagent for laboratory use. Its viscosity-sensing properties make it a valuable tool for studying the physical properties of biological systems. |
| Molecular Formula |
C16H15N3
|
|---|---|
| Molecular Weight |
249.3104
|
| Exact Mass |
249.127
|
| CAS # |
58293-56-4
|
| PubChem CID |
2963
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.23 g/cm3
|
| Boiling Point |
470.7ºC at 760 mmHg
|
| Flash Point |
214.6ºC
|
| Index of Refraction |
1.634
|
| LogP |
2.88
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LROAUBRDKLVBCP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15N3/c17-10-13(11-18)7-12-8-14-3-1-5-19-6-2-4-15(9-12)16(14)19/h7-9H,1-6H2
|
| Chemical Name |
2-(1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-7-ylmethylidene)propanedinitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~250.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0111 mL | 20.0554 mL | 40.1107 mL | |
| 5 mM | 0.8022 mL | 4.0111 mL | 8.0221 mL | |
| 10 mM | 0.4011 mL | 2.0055 mL | 4.0111 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
